This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SILVER SPRING, Md., May 9, 2013 (GLOBE NEWSWIRE) --
Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology and clinical stage provider of natural products and cell and gene therapy solutions for the treatment of diseases, announces today that
The KonLin Letter has released its May 2013 edition which features Nuvilex, its technologies and the upside potential in both the short and long term.
Leading analyst and
TheKonLin Letter publisher Konrad Kuhn, who has staggered Wall Street for three decades with predictions such as the start of the bull market in 1982, subsequent correction in 1987, the financial meltdown leading to the market collapse in 2008, shifts in interest rates and more, detailed why he sees an inevitable appreciation in the value of Nuvilex in coming years in the latest iteration of his popular publication.
In the May edition, Kuhn discusses:
Nuvilex's "blockbuster" cell encapsulation technology for cancer, diabetes is a "true platform that could benefit countless indications;"
How Nuvilex's Phase I/II clinical trial data outperformed today's "gold standard" for pancreatic cancer;
How diabetes drugs could potentially be eliminated by Nuvilex's cell encapsulation technology; and
Nuvilex's subsidiary Medical Marijuana Sciences and the adaptation of the living cell technology into the medical cannabis industry
A large portion of the report also focuses on the latest short squeeze data released by Buyins.net in April that "indicated the [NVLX] stock could move $2.00 higher." Kuhn concurs with that evaluation, stating "we could see a staircase climb to our 1
st price target of $0.50 - $0.60" and "With a break above $0.875, the blood will be running off the tape due the predictive massive short squeeze, propelling the stock to our theoretical target of $1 - $2, matching Buyin.net's SS projection."
Dr. Robert Ryan, President and CEO of Nuvilex, stated, "We are very pleased that
The KonLin Letter continues to see the potential value in our company based upon our fundamentals. Konrad Kuhn has a long and distinguished track record of uncompensated and unbiased analyses of Nuvilex as well as both the broad markets and small capitalization stocks. His prescient calls of market moves and undervalued companies are impeccable and we're excited he has recognized and spoken so favorably of Nuvilex in his latest report."
About Nuvilex Nuvilex, Inc. (OTCQB:NVLX) has been a provider of all-natural products for many years. The company has been expanded to increase its natural product-based footprint through medical marijuana studies. We are an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for research and medicine. New developments by our company and subsidiaries will be substantial as we have been working on many fronts to move us forward. Our company's offerings will ultimately include cancer, diabetes and other treatments using the Company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development.
Safe Harbor Statement
This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.